Meizhou: Sports Culture and Industry Development Summit Forum was held in jiaying university.

Text, map/Lai Jiahua Wei Jianfeng

On May 18th, a summit forum on sports culture and industrial development was held in jiaying university, where many domestic experts and scholars gathered to discuss sports culture and industrial development. Wu Qi, Secretary of the Party Committee of jiaying university, Liao Zhicheng, Vice President, David Shen, Director of Scientific Research Department of jiaying university, Lai Bingsen, Executive Dean of Institute of Physical Education, Du Guangning, Dean of Football (Industry) College, Chen Yingming, Second-level Investigator of Meizhou Sports Bureau, and other jiaying university school leaders and relevant persons in charge of Meizhou Sports Bureau and Football Association attended the event.

The Summit Forum on Sports Culture and Industrial Development was held in jiaying university.

The theme of this forum is the organic integration of football, industry and leisure to promote the construction of national football key development cities. Liu Dongfeng, professor of Shanghai Institute of Physical Education, Zhou Jieyou, vice president of School of Leisure Sports and Management of Guangzhou Institute of Physical Education, Li Pei, associate professor of South China Normal University, Liu Hongyou, PhD supervisor of School of Physical Education of South China Normal University, and deputy director of Shanghai Oriental Sports Evaluation Consulting and Evaluation Center were invited to give keynote speeches by Hui Zhen and other experts and scholars.

Liu Dongfeng, a professor at Shanghai Institute of Physical Education, gave a keynote speech.

Hui Zhen, deputy director of Shanghai Oriental Sports Evaluation Consulting and Evaluation Center, gave a keynote speech.

Liu Hongyou, Ph.D. Supervisor, School of Sports Science, South China Normal University, gave a keynote speech.

Zhou Jieyou, Vice President of School of Leisure Sports and Management, Guangzhou Institute of Physical Education, gave a keynote speech.

Li Pei, associate professor of South China Normal University, gave a keynote speech.

In his speech, Liao Zhicheng said that jiaying university made full use of the unique advantage of being in the "hometown of football", actively integrated human resources, innovatively built a scientific research platform, strived to cultivate high-quality football talents, carried out fruitful research and inheritance of football culture, and actively served the development of football in Meizhou and even the country.

In recent years, the football teaching and research team in jiaying university has undertaken more than 40 football scientific research and teaching reform projects, and established Guangdong collaborative education platform "Southern Football Innovative Talents Training Collaborative Center" and Guangdong Social Science Association "Football Culture and Industry Research Center" and other platforms. This summit forum on sports culture and industrial development is of great significance for promoting the discipline construction of the school to a higher level and promoting the development of sports industry in Meizhou, especially the development of football industry.

Experts pointed out that the goal orientation of sports city development must be adapted to the development goal orientation of the city itself; Top-level events are the most direct and effective means to reflect the influence and radiation of sports cities, and can build a combination strategy of fixed brand events+top professional leagues+single top-level events; Socialization, living and industrialization of sports are the fundamental support for the construction of sports cities. Meizhou, the hometown of football, should optimize the characteristic industrial structure and improve the traffic, accommodation and urban environment; We should cultivate Hakka football culture, excavate history, stories and integrate into education; We can develop multi-sports economy and attach importance to the integration of youth training, cost and physical education.

Nature writes: In the next 30 years, cancer will cost the world 25 trillion US dollars.

Monoclonal antibody against B-cell psoriasis leukemia, a target of cancer artificial intelligence

①Nature:Cancer will cost the world $25 trillion over next 30 years

In the next 30 years, cancer may cost the world $25 trillion.

DOI :10.1038/d41586-023-00634-9

②Seminars in Cancer Biology:Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction

Review: Application and development of artificial intelligence in the field of precision oncology: new antigen recognition, antibody design and immunotherapy response prediction.

DOI :10.1016/j.semcancer.2023.02.007

③Molecular Cancer:CD39/CD73/A2AR pathway and cancer immunotherapy

Review: New progress in pathophysiological function of CD39/CD73/A2AR pathway in cancer development, metastasis and drug resistance.

DOI :10.1186/s12943-023-01733-x

④Immunity:B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection

B cell receptor signal transduction in germinal center prolongs the survival of B cells and initiates the selection of B cells.

DOI :10.1016/j.immuni.2023.02.003

⑤Frontiers in Immunology:Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis

The metabolic recombination of miR-31-5p in keratinocytes determines the intervention on psoriasis.

DOI :10.15252/emmm.202215674

⑥Journal of Hematology & Oncology:Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

The latest drug research and new scheme progress of American Society of Hematology (ASH) for acute myeloid leukemia (AML)
DOI :10.1186/s13045-023-01411-x

⑦FDA extended the review of adult Roctavian with severe hemophilia A because of "significant changes in a large number of additional data"

⑧ A small molecule MET inhibitor, gumetinib, which was developed by Shanghai Institute of Pharmacology, China Academy of Sciences, was approved for marketing, and it was used for locally advanced or metastatic non-small cell lung cancer (NSCLC) with the jump mutation (METex14 jump) in exon 14 of mesenchymal-epithelial transforming factor (MET).

⑨ The clinical study of Relma-cel targeting CD19 for first-line high-risk large B-cell lymphoma was officially launched.

⑩ Lilly will terminate the research and development of Solanezumab for Alzheimer’s disease because it fails to slow down the cognitive decline of preclinical Alzheimer’s patients.

The world of scientific exploration is full of challenges. AtaGenix pays tribute to every pioneer and is more committed to becoming your trusted partner!